Autotelicbio

Quick facts

Phase 3 pipeline

• ATB-1011 · Immunology
  ATB-1011 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.
• ATB-1012 · Immunology
  ATB-1012 is an autotelic biologic designed to modulate immune tolerance and promote self-directed therapeutic activity.
• ATB-1013 · Immunology / Fibrosis
  ATB-1013 is an autotaxin inhibitor that reduces lysophosphatidic acid (LPA) production to modulate immune and fibrotic responses.

Phase 1 pipeline

• ATB-101, ATB-1011, ATB-1012
• ATB-320

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Autotelicbio portfolio CI brief
• Autotelicbio pipeline updates RSS